Prophylaxis

Dr. Manuel D Carcao
MD, MSc

Dr. Carcao is a Haematologist in the Division of Haematology/Oncology, and Professor of Paediatrics at the University of Toronto. He is Director of the Haemophilia and Bleeding disorders’ program at the Hospital for Sick Children.

Dr. Carcao received his medical degree in 1990 and a Master of Science degree in Clinical Epidemiology in 2007 from the University of Toronto. He joined the division of Haematology/Oncology as a faculty member in 1999.

Dr Carcao was President of the Association of Hemophilia Clinic Directors of Canada (2006-08) and Chair of the Canadian Paediatric Thrombosis & Haemostasis Network (2016-18). He is the author of over 200 peer-reviewed papers and textbook chapters. He is a prolific speaker giving talks throughout the world including plenary sessions at WFH, ISTH and other international meetings.

His research interests include congenital bleeding disorders, genetics, prophylaxis needs, pharmacokinetics, and inhibitor development; childhood immune thrombocytopenia; hereditary spherocytosis and more recently in the medical management of vascular malformations.

In 2023 he was awarded the Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research – a 5-10 year chair whose goal is to develop a Vascular Anomalies program and center.

Key Publications

1. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-684.

2. Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. J Thromb Haemost. 2019;17(7):1085-1096.

3. Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143-148.

4. Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results [published correction appears in Blood. 2023 Mar 23;141(12):1495]. Blood. 2022;139(26):3699-3707.

Current Positions/Chairs:

  • Paediatric Haematologist/Oncologist
    Division of Haematology/ Oncology
  • Professor
    Department of Paediatrics at the Hospital for Sick Children
  • Director
    Haemophilia Clinic and Haemostasis Program
  • Associate Scientist/Clinician Investigator
    Research Institute at the Hospital for Sick Children
  • Chair
    Hak-Ming and Deborah Chiu Chair in Paediatric Translational Research
  • Member
    International Prophylaxis Study Group-Prophylaxis Expert Working Group

Key Institutions

  • The Hospital for Sick Children
    Division of Haematology/ Oncology
    Toronto, Canada

Research Interests

  • Congenital bleeding disorders
  • Genetics
  • Prophylaxis needs
  • Pharmacokinetics
  • Inhibitor development
  • Childhood immune thrombocytopenia
  • Hereditary spherocytosis
  • Medical management of vascular malformations

Achievements

  • ICMR -NIIH Diamond Jubilee “Oration Award for the year 2022
  • Best Team Award to Dr. M Joseph John at the One-Week online course on Health Research Methodology and Evidence Based Medicine (February 2022)
  • Melpadom Attumalil Georgekutty Young Scientist Award-2013 of the Marthoma Church taking into consideration of outstanding contribution in the field of Science and Technology
  • World Federation of Haemophilia “Twin of the Year 2013” Award for the contributions in the haemophilia work through the twinning programme with Henry Ford Hospital, Detroit, USA
  • East Asian Haemophilia Federation Travel Award -Oral paper at Nara, Japan (November 13-15, 2015)

Publications

April 24, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
April 21, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5): e447 - e450
December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
June 20, 2015

Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20–25, 2015 – Toronto, Canada)
Authors
Carcao, M on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.
Citation
June 20, 2015

Prophylaxis practices in children and adults with inhibitors

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20 - 25, 2015 – Toronto, Canada)
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation